How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX)

Simply Wall St

Tue, February 17, 2026 at 4:10 PM GMT+9 5 min read

In this article:

TVTX

-9.08%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Travere Therapeutics’ updated fair value estimate of $42.36, up from $41.64, reflects fresh Street research that is reworking revenue growth expectations and the risk profile around the Filspari regulatory path. With the discount rate now at 7.25% versus 7.17%, and the projected revenue growth rate at 32.08% versus 31.69%, the latest price target reset captures both a slightly higher required return and a modestly stronger outlook for the top line in current models. As you follow these shifts in assumptions, stay tuned to see how you can keep track of the evolving narrative around Travere’s valuation drivers over time.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Travere Therapeutics.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Leerink highlights the FDA extension of the Filspari sNDA review in focal segmental glomerulosclerosis as removing what it describes as the worst case scenario of a Complete Response Letter, which it views as encouraging for the regulatory path.

Leerink notes that the FDA requests focus on further characterizing clinical benefit, with no additional safety or manufacturing data requested. The firm reads this as a cleaner path to addressing questions on efficacy rather than product quality.

Leerink reiterates its Outperform rating following the update, signaling continued confidence in Travere Therapeutics’ execution on the Filspari program and its importance to the longer term growth story.

Piper Sandler and BofA both raise their Travere Therapeutics price targets in early February 2026, which points to a set of models that, at least at those firms, supports higher valuation assumptions than before.

🐻 Bearish Takeaways

BofA also cuts its Travere Therapeutics price target in mid January 2026, which suggests the firm had earlier reservations reflected in its valuation work even though specific concerns are not detailed in the summary provided.

The PDUFA extension for Filspari, while viewed positively by Leerink compared with a potential Complete Response Letter, still introduces timing and outcome uncertainty that some investors may see as a near term risk to execution and to how quickly any Filspari assumptions in valuation models may be realized.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

Story Continues  

NasdaqGM:TVTX 1-Year Stock Price Chart

What’s in the News

The FDA extended the review timeline for Travere Therapeutics' supplemental New Drug Application for FILSPARI in focal segmental glomerulosclerosis, setting a new PDUFA action date of April 13, 2026, after the company submitted additional data on clinical benefit in FSGS.

The FDA classified Travere's additional responses as a Major Amendment to the sNDA and did not request any new safety or manufacturing information for FILSPARI, so the focus of the review remains on clinical benefit.

If the sNDA is approved, FILSPARI would become the first FDA approved medication for FSGS, a rare kidney disorder estimated to affect more than 40,000 patients in the U.S., with similar prevalence in Europe according to the company.

FILSPARI is already fully approved by the FDA and European Medicines Agency to slow kidney function decline in adults with IgA nephropathy. The current FSGS filing is supported by Phase 3 DUPLEX and Phase 2 DUET data, including statistically significant proteinuria reductions versus irbesartan and two year results published in the New England Journal of Medicine, where FILSPARI was reported as well tolerated across trials.

How This Changes the Fair Value For Travere Therapeutics

Fair Value: The modeled fair value estimate is now US$42.36, compared with the prior US$41.64. This reflects updated inputs around the business and risk profile.

Discount Rate: The discount rate is now 7.25% versus 7.17%, indicating a slightly higher required return assumption in the model.

Revenue Growth: The projected revenue growth rate is now 32.08% compared with 31.69%, signaling a modestly higher top line outlook in the forecast period used.

Net Profit Margin: The assumed net profit margin is now 28.72% versus 27.80%, pointing to slightly stronger modeled profitability over time.

Future P/E: The future P/E multiple applied in the model is now 16.49x compared with 16.85x, which indicates a modestly more conservative valuation multiple being used on future earnings.

🔔 Never Miss an Update: Follow The Narrative

Narratives on Simply Wall St let you connect a company’s story to the numbers by setting out your view on its business, linking that to forecasts for revenue, earnings and margins, then tying it all together with a fair value estimate. They sit on the Community page, update automatically when news or earnings arrive, and help you decide what to do by comparing Fair Value to today’s share price in one clear framework.

Head over to the Simply Wall St Community and follow the Travere Therapeutics Narrative to stay on top of how the story and valuation are evolving:

How FILSPARI’s rare kidney disease positioning and potential FSGS label expansion are framed as a first mover opportunity for revenue and margins.

Why the author links regulatory progress, recurring revenue and cost discipline to the current forecast and fair value for Travere.

Which key risks, from competition to pricing pressure and regulatory timing, could challenge the thesis and the implied valuation range.

You can read the original Travere Therapeutics Narrative in full here: TVTX: FSGS Regulatory Extension And Kidney Data Will Drive A Constructive Outlook. Curious how numbers become stories that shape markets? Explore Community Narratives

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include TVTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info